New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Targeted oncology

• Publication date

  2007-01-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11523-006-0040-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial

  2008cited by this paper
• Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival.

  2007cited by this paper
• Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC).

  2006cited by this paper
• Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC).

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3.

  2006cited by this paper
• Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis.

  2006cited by this paper
• Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.

  2006cited by this paper
• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC).

  2006cited by this paper
• Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).

  2006cited by this paper
• EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response.

  2006cited by this paper
• Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

  2006cited by this paper
• Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma.

  2006cited by this paper
• Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412.

  2006cited by this paper
• Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer.

  2006cited by this paper
• Phase II study of Sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research-EWIV (CESAR).

  2006cited by this paper
• A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC).

  2006cited by this paper
• Understanding the importance of smart drugs in renal cell carcinoma.

  2006cited by this paper
• Results of an analysis of cardiac function in 2,812 patients treated with lapatinib.

  2006cited by this paper
• 10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer.

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006influential reference
• Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).

  2006cited by this paper
• A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts).

  2006cited by this paper
• Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma

  2006cited by this paper
• Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit216 multicenter phase III trial.

  2006cited by this paper
• A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC).

  2006cited by this paper
• Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study

  2006cited by this paper
• Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.

  2006cited by this paper
• Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease.

  2006cited by this paper
• Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer.

  2006cited by this paper
• Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma.

  2006cited by this paper
• Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.

  2006cited by this paper
• Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

  2006cited by this paper
• Tumor-induced lymphangiogenesis: a target for cancer therapy?

  2006cited by this paper
• A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer

  2005cited by this paper
• Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

  2005cited by this paper
• Raf: a strategic target for therapeutic development against cancer.

  2005influential reference
• Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

  2005cited by this paper
• Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression

  2005cited by this paper
• Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer

  2005cited by this paper
• Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

  2005cited by this paper
• Renal cell carcinoma: current status and future prospects.

  2005cited by this paper
• Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy

  2005cited by this paper
• Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.

  2005cited by this paper
• An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

  2005cited by this paper
• Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

  2005cited by this paper
• Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells

  2005cited by this paper
• Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

  2005cited by this paper
• Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

  2005cited by this paper
• RET Proto-Oncogene: A Review and Update of Genotype–Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine Tumors

  2005influential reference
• Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors

  2005cited by this paper
• Humor and oncology.

  2005cited by this paper
• The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.

  2005cited by this paper
• A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer

  2004cited by this paper
• Su-11248 Sugen.

  2004cited by this paper
• A Phase II Study of Docetaxel in Patients with Metastatic Carcinoid Tumors

  2004cited by this paper
• RET and neuroendocrine tumors.

  2004influential reference
• Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).

  2004cited by this paper
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

  2004cited by this paper
• Biology of gastrointestinal stromal tumors.

  2004influential reference
• SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

  2004cited by this paper
• Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  2003cited by this paper
• SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.

  2003cited by this paper
• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  2003cited by this paper
• A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• Double target for tumor mass destruction.

  2003cited by this paper
• Nephrectomy in metastatic renal cell carcinoma

  2003cited by this paper
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003cited by this paper
• Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

  2003cited by this paper
• Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

  2003cited by this paper
• Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

  2003cited by this paper
• Platelet-derived growth factor signaling and human cancer.

  2003cited by this paper
• BAY 43-9006: preclinical data.

  2002influential reference
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.

  2002cited by this paper
• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  2001cited by this paper
• Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.

  2001cited by this paper
• A Phase II study of high‐dose paclitaxel in patients with advanced neuroendocrine tumors

  2001cited by this paper
• Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

  2000cited by this paper
• Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

  2000cited by this paper
• Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.

  2000cited by this paper
• Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

  2000cited by this paper
• Chemotherapy for renal cell carcinoma.

  2000cited by this paper
• Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase.

  1999cited by this paper
• Chemotherapy for renal cell carcinoma.

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

  1999cited by this paper

• Indolin-2-one based scaffold for the development of multi- kinase inhibitor: Focus on sunitinib as an anticancer agent

  2023cites this paper